18F-FDG PET and myocardial viability assessment: Trials and tribulations

Journal of Nuclear Medicine

Volumn 51, Issue 4, 2010, Pages 505-506

  Allman, Kevin C ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC HEART DISEASE; MITRAL VALVE REGURGITATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; SHORT SURVEY; CLINICAL TRIAL; HEART; NOTE; PHYSIOLOGY; SCINTISCANNING; TISSUE SURVIVAL;

CLINICAL TRIALS AS TOPIC; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TISSUE SURVIVAL;

EID: 77950928646     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.069849     Document Type: Short Survey

References (11)

1. 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2009; 51:567-574.
2. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-2012.
3. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645-2657.
4. Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: the role of viability testing. J Am Coll Cardiol. 2005;46:567-574.
5. Tillisch J, Brunken R,Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl JMed. 1986;314:884-888. (Pubitemid 16126116)
6. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151-1158.
7. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693-1700.
8. Cornel JH, Bax JJ, Elhendy A, et al. Agreement and disagreement between "metabolic viability" and "contractile reserve" in akinetic myocardium. J Nucl Cardiol. 1999;6:383-388.
9. Roes SD, Kaandorp TA, Marsan NA, et al. Agreement and disagreement between contrast-enhanced magnetic resonance imaging and nuclear imaging for assessment of myocardial viability. Eur J Nucl Med Mol Imaging. 2009;36:594-601.
10. Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol. 2005;46:1264-1269.
11. D'Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2:1060-1068.